Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus Oncology is supported by a differentiated commercial base and a pipeline that could meaningfully expand that base, with Loqtorzi as the only FDA-approved and commercially available U.S. treatment for recurrent or metastatic nasopharyngeal carcinoma and management targeting ~$150-200M peak revenue to cover COGS, SG&A and royalties. The stock also screens as undervalued, at roughly ~$179M market cap or ~0.75x peak NPC Loqtorzi sales, while the pipeline offers upside because most regimens keep Loqtorzi as the PD-1 backbone, allowing Coherus to capture both direct PD-1 revenue and combination value. Fundamental support is reinforced by encouraging early clinical signals, including 1L ESCC tagmokitug data with a 75% confirmed ORR at cutoff and guidance for FY26 Loqtorzi revenue of $57M-$62M, alongside a modeled path to profitability starting in FY30.

Coherus Oncology is viewed negatively because a meaningful share of Loqtorzi economics is immediately encumbered by partner obligations, including a low-20% royalty, up to $380M in milestones, and a 5% revenue participation payment on U.S. net sales, which limits operating leverage even if sales grow. The balance sheet is also tight, with $105.3M in cash, cash equivalents and marketable securities at the end of 2Q26 against $37.2M in debt, a new $55M term loan, guided FY26 operating expenses of $170-175M, and an expected need for future equity raises that could dilute shareholders. Fundamentally, the pipeline remains highly uncertain because casdozokitug and tagmokitug rely on small, interim, largely single-arm data, while clinical, regulatory, competition, and safety risks could leave the company dependent on modest NPC-only Loqtorzi sales if broader development fails.